Stromectol is an ivermectin antiparasitic tablet for adults and eligible children. It is used for selected parasitic infections, where it disrupts nerve and muscle signalling in susceptible parasites.
Stromectol is a tablet containing ivermectin; the dose is stated on the pack — follow the leaflet. It is used for certain parasitic infections and works by disrupting nerve and muscle signalling in susceptible parasites. Ivermectin is an antiparasitic medicine and belongs to the avermectin group of antiparasitic agents.
Stromectol contains ivermectin, an antiparasitic medicine. The dose is stated on the pack — follow the leaflet, and the product is supplied as tablets in a blister pack. Ivermectin belongs to the avermectin group of antiparasitic agents.
The medicine is used against selected nematodes and ectoparasites. Its approved use depends on the diagnosis, local treatment guidance, age, body weight, and medical history. Stromectol is not a general treatment for every worm infection, and the same dose is not suitable for every condition.
The tablet strength matters. The prescribed number of tablets depends on body weight and the condition being treated.
The exact regimen depends on the diagnosed infection, body weight, age, liver function, and local prescribing guidance. Stromectol tablets are taken orally.
For many adult antiparasitic regimens, ivermectin is calculated around body weight rather than as a fixed number of tablets. The commonly used target for several indications is approximately 200 micrograms per kilogram, but this does not apply to every infection or every patient. Children weighing below the permitted threshold require a separate treatment decision.
Swallow tablets whole unless a prescriber or pharmacist has provided a specific method for the prescribed product. Do not use ivermectin to treat an undiagnosed rash, itching, or abdominal symptoms simply because parasites are suspected.
Ivermectin binds to glutamate-gated chloride channels found in many invertebrate nerve and muscle cells. This increases chloride-ion flow, causing paralysis and death of susceptible parasites while human cells are affected differently because they lack these channels in the same form. The pharmacological action is described in the FDA prescribing information and international antiparasitic guidance [1].
Ivermectin acts mainly on chloride channels in parasites. The resulting electrical disturbance reduces movement, feeding, and survival. In infections caused by intestinal nematodes, this action helps remove susceptible parasites from the body.
For onchocerciasis, ivermectin reduces the number of circulating microfilariae. It does not directly eliminate adult worms, so treatment plans can involve repeated doses or organised programmes. For strongyloidiasis, ivermectin targets the parasitic nematode responsible for infection.
The medicine is used against selected nematodes and ectoparasites. Its approved use depends on the diagnosis, local treatment guidance, age, body weight, and medical history. Stromectol is not a general treatment for every worm infection, and the same dose is not suitable for every condition.
The medicine has activity against some roundworms and certain external parasites. It does not treat bacterial infections, viral infections, or every type of intestinal worm. A correct diagnosis matters because parasites differ in their biology and drug sensitivity.
Ivermectin can also be prescribed in selected settings for scabies. This use requires attention to local clinical guidance, contact treatment, laundering advice, and the possibility of reinfestation. Oral ivermectin may be combined with a topical approach in difficult or extensive cases, but the choice belongs to the treating clinician.
The medicine is not an antiviral treatment. Clinical evidence has not established ivermectin as a treatment for COVID-19, and the European Medicines Agency advised against using it for prevention or treatment of COVID-19 outside clinical trials [3].
The World Health Organization describes ivermectin as an important medicine for several neglected tropical diseases [2].
The choice between antiparasitic approaches depends on the organism, its location in the body, pregnancy status, age, immune function, and resistance patterns.
| Approach | Main role | Key limitation |
|---|---|---|
| Ivermectin | Selected nematode infections and some ectoparasitic conditions | Does not cover every parasite and requires weight-based selection |
| Albendazole-class treatment | Several intestinal helminth infections | May be unsuitable for certain infections, ages, or liver conditions |
| Topical antiparasitic treatment | Some infestations affecting the skin | Application can be difficult when the affected area is extensive |
Ivermectin may be preferred when a susceptible parasite responds well to systemic treatment or when applying topical therapy is impractical. An albendazole-class medicine may be selected for a different worm species or anatomical site. Topical treatment can be useful when infection is limited to the skin and systemic exposure should be minimised.
A clinician may also consider stool testing, skin examination, blood testing, travel exposure, household symptoms, and immune status before choosing treatment. Drug selection should follow the organism rather than the symptom alone.
People with heavy Loa loa infection can develop serious neurological reactions after ivermectin. Travel and residence history should be disclosed before treatment, especially when exposure occurred in Central or West African endemic areas.
Tell the prescriber about anticoagulants, sedatives, medicines for seizures, and treatments that affect liver enzymes. Warfarin users may require closer monitoring because changes in anticoagulant response have been reported with ivermectin. Do not combine ivermectin with veterinary antiparasitic products.
Stromectol is not suitable for everyone. Stromectol is not for you if you have a serious ivermectin allergy, possible Loa loa infection, or a condition requiring another treatment. Extra medical assessment is important if you are pregnant or breastfeeding, have liver problems, are below the approved age or weight threshold, have neurological symptoms, or take medicines that may increase drowsiness or affect drug metabolism.
Common adverse effects vary with the infection being treated and the number of parasites present. Possible reactions include nausea, diarrhoea, abdominal discomfort, dizziness, headache, fatigue, itching, and skin rash. Some symptoms can reflect the body’s response to dying parasites rather than direct toxicity from ivermectin.
In onchocerciasis, inflammatory reactions may include fever, itching, swollen lymph nodes, muscle or joint pain, fast heart rate, low blood pressure, or eye symptoms. These reactions can be more pronounced when the microfilarial burden is high. The South African Health Products Regulatory Authority and international prescribing information describe the need for clinical monitoring in relevant patients.
Seek urgent medical attention for facial swelling, difficulty breathing, fainting, severe blistering, confusion, marked weakness, or a sudden change in vision. Rare neurological effects have been reported, especially after excessive exposure or in people with particular parasitic infections.
Nausea may be easier to tolerate when the prescribed administration instructions are followed exactly. Do not add alcohol, sedatives, or other medicines that cause drowsiness without checking for an interaction.
One practical detail is easy to miss: itching may continue for days after successful treatment of scabies because the skin remains inflamed. Persistent itching does not automatically prove that the medicine failed, but new burrows or live mites need reassessment.
Another detail matters in onchocerciasis. Severe headache, low blood pressure, breathing difficulty, or confusion after treatment requires prompt medical assessment because a heavy microfilarial reaction can become serious.
Several errors can reduce treatment success or increase risk:
Do not crush several tablets together into food unless a healthcare professional has given a suitable administration instruction. Uneven mixing can lead to an incomplete dose, especially when the tablets are divided among children.
In clinical practice, doctors usually begin by confirming that the suspected parasite matches ivermectin’s spectrum. A positive symptom pattern alone is not enough because eczema, allergic dermatitis, bacterial infection, inflammatory bowel disease, and medication reactions can resemble parasitic disease.
Prescribers also calculate the regimen from body weight. A 3 mg tablet is a strength, not a universal adult dose. The total number of tablets may differ substantially between two adults with the same diagnosis if their weights differ.
Treatment response also depends on reinfection and untreated contacts. With scabies, close household contacts may need assessment, and clothing or bedding may require coordinated cleaning. Treating one person while an infected contact remains untreated can lead to renewed symptoms.
Doctors pay close attention to immune status in strongyloidiasis. People receiving corticosteroids or other immunosuppressive treatment can develop severe or disseminated infection, making diagnosis and follow-up more urgent. The Centers for Disease Control and Prevention identifies strongyloidiasis as a condition that can become dangerous in immunosuppressed patients [4].
Stromectol is used for selected parasitic infections caused by susceptible organisms, including certain nematode infections and some ectoparasitic conditions. The exact indication depends on the diagnosis and local prescribing guidance. It is not a general treatment for every worm, rash, or gastrointestinal complaint. The 2023 WHO guidance supports ivermectin use in specific parasitic disease programmes, while treatment outside those indications requires clinical judgement.
The number of tablets depends on body weight and the infection being treated. Each tablet contains 3 mg of ivermectin, but the prescribed regimen may involve one or several tablets. Many regimens use a weight-based target near 200 micrograms per kilogram, while some conditions require a different schedule. The 2018 FDA prescribing information should be used with the diagnosis-specific regimen rather than a universal tablet count.
Oral ivermectin may be used for selected scabies cases, including extensive, crusted, recurrent, or difficult-to-treat infection. The timing of repeat doses and the possible use of topical treatment depend on clinical findings and local guidance. Close contacts may also need assessment, because untreated contacts can cause reinfestation. South African clinical practice should follow the 2022 SAHPRA-recognised product information and local infectious-disease guidance.
The time to improvement varies by parasite and by the body’s inflammatory response. Abdominal symptoms may improve at different times from stool-test results, while scabies-related itching can continue after mites have been eliminated. New lesions, visible parasites, or worsening symptoms require reassessment rather than automatic repeat dosing. The 2021 EMA information on ivermectin emphasises that treatment response depends on the indication and clinical context.
Pregnancy requires an individual risk assessment. Ivermectin should not be taken during pregnancy unless the expected benefit justifies possible risk and the prescriber has selected it. The decision depends on the parasite, severity of infection, gestational stage, and available alternatives. The 2023 WHO recommendations for parasitic disease control should be applied alongside the patient’s clinical circumstances.
For a one-time regimen, do not automatically repeat the dose after uncertainty; confirm the intended schedule with the prescribing service. For a multi-dose course, take the missed dose when remembered unless the next dose is close, and never double the next administration. The correct action can differ by indication, so the diagnosis and schedule must be considered together. The 2024 CDC treatment guidance for strongyloidiasis supports indication-specific dosing rather than a single approach for all infections.
Children must meet the relevant weight and age requirements before ivermectin is considered. The dose is calculated from body weight, and adult tablet use without medical direction can cause dosing errors. Children with neurological disease, liver problems, or possible exposure to Loa loa need additional assessment. National regulatory information and the product’s approved prescribing framework should guide paediatric treatment. The 2018 FDA prescribing information also sets out the approved paediatric framework for Stromectol.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took the prescribed ivermectin course for a confirmed intestinal infection. The tablets were easy to swallow, and the stomach discomfort settled after a day. My follow-up test was more useful than judging the result from symptoms alone.
The itching from scabies lasted longer than I expected after treatment. I initially thought the tablets had failed, but the clinician explained that inflamed skin can stay itchy. Household treatment made a bigger difference than taking extra tablets.
I felt dizzy for several hours after the dose and avoided driving. The symptoms passed, but I would plan the treatment for a time when work and travel are not necessary.
The treatment helped, but I had nausea and loose stools during the first day. My main mistake was assuming another dose would help faster. The prescribed schedule was sufficient.
